Bristol/Gilead Triple Combination HIV Therapy Has Back-Up
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol-Myers Squibb and Gilead are developing a "back-up" formulation of the fixed-dose combination of Sustiva and Truvada that is the subject of their joint venture